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Available online 26 April 2016Background:Malignant peritonealmesothelioma (MPM) canmasquerade as anovarian epithelial neoplasm,with
very similar presenting clinical symptoms and imaging ﬁndings. The gold standard in differentiating between
these two diagnoses lies in tissue pathology.
Case report: This is a case of MPM that was initially misdiagnosed as ovarian cancer based on family history, im-
aging, and surgical ﬁndings. Tissue diagnosis preoperatively would have changed the planned procedure. Retro-
spectively, after the diagnosis of MPM, the patient was found to have had an indirect exposure to asbestos
through her father.
Conclusions: This case highlights the importance of keeping a broad differential when diagnosing ovarian malig-
nancies, collecting both family and social histories (including screening for exposure to asbestos), and the beneﬁt
of obtaining tissue diagnosis when MPM is suspected.






Malignant mesothelioma is an aggressive tumor of serosal surfaces,
most commonly involving the pleura followed by the peritoneum
(Boffetta, 2007). Incidence rates range between 0.2 and two cases per
million in women (Boffetta, 2007), versus approximately 6.8 cases per
million of serous primary peritoneal cancer (Goodman and Shvetsov,
2009). Of 3300 new diagnoses of mesothelioma per year in the United
States, approximately 10–15% are peritoneal (Goodman and Shvetsov,
2009; Surveillance, Epidemiology, and EndResults (SEER) Program,
2004), with a mean age at diagnosis of 53 (Teta et al., 2008). A study
of 10,589 cases of mesothelioma reported to the Surveillance, Epidemi-
ology, and End Results (SEER) database between 1973 and 2005 dem-
onstrated that females account for 44% of peritoneal cases compared
to 19% of pleural primaries (Surveillance, Epidemiology, andthelioma initially misdiagnosed
ing a broad differential when
and social histories including
ng tissue diagnosis when MPM
cology, 525 E. 68th Street, Suite
. This is an open access article underEndResults (SEER) Program, 2004; Teta et al., 2008). Ovarian involve-
ment in mesothelioma is rare. In a United Kingdom registry
encompassing 24 years of data on mesotheliomas, 0.03% of
mesothelioma-related deaths had presented with an ovarian mass
(Merino, 2010). Pleural and peritoneal mesotheliomas share many
risk factors, the most common of which is exposure to asbestos. In a
study of 52womenwithmalignantmesothelioma, indirect asbestos ex-
posure, as measured by husbands and fathers working in asbestos-
related industries, led to an increase in relative risk by ten for develop-
ing malignant mesothelioma (Vianna and Polan, 1978).1.2. Clinical presentation and diagnosis
The most common presenting features in patients with malignant
peritoneal mesothelioma (MPM) are strikingly similar to that of ovarian
cancer and include ascites, abdominal distention, abdominal pain, and
occasionally bowel obstruction (Sugarbaker et al., 2003). In cases with
ovarian involvement, MPM can appear intraoperatively as primary
ovarian cancer with intraperitoneal spread (Clement et al., 1996). The
key to differentiating the two diagnoses lies in histologic differences in
the appearance of papillae and degree of nuclear atypia. Because it is a
rare entity amongwomen, the pathologistmay not consider the diagno-
sis or even have experience in identifying characteristic histopathologic
features (Baker et al., 2005). However, early distinction between the
two etiologies is crucial because treatment protocols vary signiﬁcantly.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Poorly differentiated pattern with solid sheets of cells.
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In the SEER cancer registry, median survival in MPM was shown to
be 10 months and the relative 5-year survival rate was 16%
(Surveillance, Epidemiology, and EndResults (SEER) Program, 2004).
Examination of this database also shows that age, tumor grade, and gen-
der are independent predictors of prognosis in MPM (Surveillance,
Epidemiology, and EndResults (SEER) Program, 2004; Teta et al., 2008).
2. Case report
This is a 51-year-old asymptomatic, postmenopausal female with a
sister diagnosed at age 49 with ovarian cancer (no BRCA testing)
found to have a thickened endometrial stripe on transvaginal ultra-
sound. An endometrial biopsy (EMB) was performed and showed atyp-
ical metaplastic epithelium and atypical mesothelial proliferation
described as a tubulopapillary proliferation of low columnar cells with
stromal hyalinization, and psammomatous calciﬁcations. She was re-
ferred to gynecologic oncology. Physical exam was benign, CT scan
was unremarkable, and tumor markers including CEA, CA 19-9, and
CA-125werewithin normal limits. She had a hysteroscopy and D&C no-
table for atrophic endometrium and endometrial polyps. The patient
desired a prophylactic bilateral salpingo-oophorectomybased on family
history. Pre-operative CT scan revealed extensive peritoneal implants, a
right adnexal mass, small pelvic ascites, sigmoid mesocolon implants,
and subcentimeter right superior diaphragmatic lymph nodes. Tumor
markers were repeated and noted to be within normal limits. Given
the ﬁndings of psamomma bodies on EMB, the patient's strong family
history of ovarian cancer and peritoneal carcinomatosis on imaging, pri-
mary ovarian cancer was suspected. The patient underwent an explor-
atory laparotomy, total abdominal hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, bilateral pelvic lymph node sampling,
appendectomy, tumor debulking, cystourethroscopy, and proctoscopy
without complication. Intraoperatively, in addition to the distinct
masses that had been noted on imaging, miliary disease and exudates
were noted diffusely throughout the peritoneum, and small and
large bowel mesenteries. The patient was optimally cytoreduced to
subcentimeter residual disease.
Final pathology revealed MPM. The morphology and immunostain-
ing pattern revealed two distinct growth patterns. The ﬁrst pattern
had distinct papillary architecture (Fig. 1) while the second pattern ap-
peared less well differentiated, consisting of solid sheets of cells (Fig. 2).
Immunohistochemistry was performedwith strong positivity for meso-
thelial markers calretinin and CK 5/6. Stains for common adenocarcino-
ma and epithelial markers including CK7, CK20, ER, D240 and BerEP4
showed patchy positivity and staining for ovarian marker PAX-8 wasFig. 1. Distinct papillary architecture of MPM, note broad papilla with hyalinized cores.negative. Overall the two growth patterns showed similar staining pat-
terns, although the solid sheets of cells had a lower percentage of cells
staining. The morphology and immunohistochemical staining pattern
weremost consistentwithMPMand thereforewas the strongly favored
diagnosis by the pathologists.
The patient was referred to medical oncology where she
underwent four cycles of cisplatin and pemetrexed. She was then re-
ferred by medical oncology to the University of Pittsburgh's Meso-
thelioma Specialty Care Center where radical tumor cytoreductive
surgery with hyperthermic intraperitoneal chemotherapy (HIPEC)
with cisplatin was performed. Intraoperatively, multifocal disease
was noted on small and large bowel mesenteries, serosal surfaces
of the right, transverse, and descending colon, gallbladder, spleen,
bilateral hemidiaphragms, as well as adherent disease on the liver
surface with invasion into subscapular liver. The surgery was un-
complicated and there was no gross residual disease. Her recovery
was unremarkable and three and six month CT scans showed no ev-
idence of disease. However, CT scan tenmonths later showed disease
progression in the peritoneum as well as new ascites. She then com-
pleted another four cycles of carboplatin and pemetrexed and video-
assisted thoracic surgery (VATS) pleurodesis for a right-sided pleural
effusion. Since that time she has had successive CT scans noting dis-
ease progression prompting treatment with gemcitabine, followed
by vinorelbine, then doxil. Currently the patient is being treated
with carboplatin and pemetrexed.
Retrospectively, with the known diagnosis of MPM, the patient's
family history was re-examined for potential risk factors predisposing
her to the development of MPM. Her father had been a seaman and de-
veloped lung asbestosis and therefore she had household exposure to
asbestos through her father.3. Discussion
MPM is a rare entity that upon initial presentation can be indistin-
guishable from ovarian cancer. Without a high clinical suspicion
among primary care physicians, gynecologists, gynecologic oncologists,
and pathologists, misdiagnosis and subsequent mismanagement are
likely. Despite the original EMB pathology and history of indirect asbes-
tos exposure, MPM was low on the differential in this case. An ovarian
cancer primary was favored given known family history, surgical and
CT ﬁndings, and overall higher incidence of ovarian malignancies.
While histologic diagnosis can be difﬁcult, it would have beneﬁtted
this patient if MPM was suspected before surgical treatment was
attempted so that HIPEC could have been administered during the
patient's initial cytoreductive surgery.
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Pre-operative tissue diagnosis can be obtained by CT-guided core
needle biopsy or laparoscopic biopsy (van Gelder et al., 1989). Histolog-
ic features and immunohistochemical staining characteristics will
usually allow the differentiation of MPM from serous and other adeno-
carcinomas. Speciﬁcally, calretinin and CK 5/6 are strongly positive in
nearly 100% of MPM, with signiﬁcantly weaker positive staining to
these markers in serous ovarian (Baker et al., 2005). When combined
with panels for epithelial and adenocarcinoma (CK7, CK20, ER, D240,
BerEP4) and ovarian markers such as PAX-8, the distinction can be
made easily. Morphologically, psammoma bodies are more common
in ovarian cancer than mesothelioma. However, psammoma bodies
were seen in our case of MPM. Examination of papillary architecture,
nuclear atypia, and mitotic rates can further aid in distinguishing
these two entities. In serous ovarian cancers, the papillae have more hi-
erarchical branching, cellular stratiﬁcation, and detached cell clusters,
whereas in MPM, the papillae are broader with hyalinized cores and
no budding. Serous ovarian cancers also have more nuclear atypia
with frequent anaplastic or bizarre nuclei and abnormal mitotic ﬁgures,
as well as higher mitotic rates (Baker et al., 2005).
3.2. Management
HistoricallyMPMpatientswere treated palliativelywith intravenous
chemotherapy, surgery, and radiation therapy yielding median survival
rates of less than a year. With the advent of complete surgical
cytoreduction and HIPEC, survival rates now approach ﬁve years (Yan
et al., 2009; Alexander et al., 2013). Standard treatment in selected pa-
tients, with no evidence of extraperitoneal spread, good performance
status, and a disease burden amenable to complete cytoreduction with
no deposits over 2 to 2.5 mm (Deraco et al., 2008), includes a combina-
tion of cytoreductive surgery and intraperitoneal chemotherapy
(Boffetta, 2007). There are no randomized controlled trials addressing
speciﬁc protocols, however the two largest multi-center studies utilize
cisplatin, mitomycin, or doxorubicin as HIPEC agents (Yan et al., 2009;
Alexander et al., 2013). For patients who are not candidates for
cytoreductive surgery plus HIPEC, systemic chemotherapy regimens
include the antifolate pemetrexed plus cisplatin or carboplatin. This
protocol is based on studies demonstrating the impact of this drug com-
bination on overall survival rates in pleural mesothelioma (Vogelzang
et al., 2003), but studies suggest a similar impact of this protocol on re-
sponse rate andmedian survival rate in patients withMPM (Jänne et al.,
2005; Carteni et al., 2009). Newdata investigating gene expression anal-
ysis in MPM tumor samples revealed a signiﬁcant difference in survival
based on expression of phosphoinositide-3-kinase (PI3K) andmamma-
lian target of rapamycin (mTOR) signaling pathways. MPM patients
with overexpression of these pathways had a shorter median survival
compared toMPMpatientswithout overexpression (24months as com-
pared to 69.5months, P= .035) (Varghese et al., 2011)). The therapeu-
tic value of mTOR inhibitors is currently being evaluated in Phases I and
II clinical trials.
4. Conclusions
Age-cohort modeling from SEER estimates that between 2005 and
2050, there will be 6900 cases of MPM diagnosed among women
(Moolgavkar et al., 2009). Given the similarities in presentationamong patients with MPM and ovarian cancer with peritoneal carcino-
matosis, many of these cases will likely present to the gynecologist or
gynecologic oncologist masquerading as an ovarian malignancy. We're
presenting a case of MPM that was initially misdiagnosed as ovarian
cancer. This case highlights the value of keeping a broad differential di-
agnosis, the importance of collecting both family and social histories
(including screening for exposure to asbestos), and the beneﬁt of
obtaining tissue diagnosis when MPM is suspected.
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